Abstracts tagged "autoantibodies"

Abstract Number: 2713 • 2015 ACR/ARHP Annual Meeting
A Novel Paradigm in the Clinical Context of Rheumatoid Arthritis: Role of Tfh and Th17 Cells in Autoimmunity
Magdalena Budziakowska¹, Arif Shahzad¹, Jerry Pounds¹, Shikha Singla¹, Jerald M. Zakem^1,2, Kismet Collins¹, Tamika Webb-Detiege¹, William E. Davis^1,2, Zongbing You³, Robert Quinet^1,2 and Xin Zhang⁴, ¹Rheumatology, Ochsner Medical Center, New Orleans, LA, ²University of Queensland School of Medicine, Brisbane, Australia, ³Tulane University Health Science Center, New Orleans, LA, ⁴Laboratory of Cellular Immunology, Institution of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of synovium, which causes progressive joint destruction and reduction in quality of life…
Abstract Number: 209 • 2015 ACR/ARHP Annual Meeting
Different Autoimmune Rheumatic Diease IgG Have Differential Effects upon Neutrophil Binding, Activation and Neutrophil Extracellular Trap Formation
Akif A. Khawaja^1,2, Charis Pericleous³, Vera M. Ripoll², Joanna C. Porter⁴ and Ian Giles⁵, ¹Centre for Inflammation and Tissue Repair, Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ⁴Centre for Inflammation and Tissue Repair, Division of Medicine, Centre for Inflammation and Tissue Repair, University College London, London, United Kingdom, ⁵Rayne Intitiute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Dysregulation of neutrophil activation and function is important in the pathogenesis of various inflammatory and autoimmune rheumatic diseases (ARDs). Neutrophil dysfunction is well recognised…
Abstract Number: 1111 • 2015 ACR/ARHP Annual Meeting
Relapse of Lupus after B-Cell Depletion Therapy Is Associated with Loss of Apoptotic Cell Clearance and Elevated Type I Interferon Responses in Lupus Prone BXD2
Hui-Chen Hsu^1,2, Zhaoqi Yan³, PingAr Yang², Qi Wu^1,2, Jennie Hamilton⁴, Jun Li⁵, Hao Li⁶, Bao Luo⁶, Laurie Harrington³ and John Mountz⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Cell, Developmntl & Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: B-cell depletion therapy (BCDT) is a promising therapy for autoimmune diseases but relapse can occur. In rheumatoid arthritis, patients who did not respond well…
Abstract Number: 1870 • 2015 ACR/ARHP Annual Meeting
A Lupus-Associated Variant in Purine Nucleoside Phosphorylase (PNP) Causes Cell Cycle Abnormalities
Yogita Ghodke-Puranik¹, Jessica M. Dorschner¹, Danielle Vsetecka¹, Shreyasee Amin², Ashima Makol³, Floranne C. Ernste², Thomas Osborn², Kevin Moder², Vaidehi Chowdhary⁴, Mark A. Jensen⁵ and Timothy B. Niewold¹, ¹Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system, autoimmune disease characterized by autoantibodies to nucleic acids and nucleosomal proteins. The type I interferon pathway is…
Abstract Number: 2785 • 2015 ACR/ARHP Annual Meeting
Association of Anti-Glutamate Receptor Subunit NR2 Antibody and Psychiatric Disorder in Patients with Primary Sjögren Syndrome
Yoshiyuki Arinuma^1,2, Yuko Sakuma³, Eisuke Ogawa², Tatsuhiko Wada⁴, Tatsuo Nagai², Sumiaki Tanaka² and Shunsei Hirohata², ¹Center for Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ³Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Sjögren syndrome (SjS) is one of the autoimmune disease characterized by the production of autoantibodies. Patients with SjS frequently observe psychiatric manifestation such as…
Abstract Number: 285 • 2015 ACR/ARHP Annual Meeting
Tobacco Smoking in Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies
Adam Schiffenbauer¹, Natalie Smith², Lisa G Rider¹ and Frederick W. Miller³, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Statistics, Purdue University, Allison Park, PA, ³Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD
Background/Purpose: Smoking has been found to be a risk or protective factor in certain autoimmune diseases. Yet, its role in the idiopathic inflammatory myopathies (IIM)…
Abstract Number: 1114 • 2015 ACR/ARHP Annual Meeting
Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity
Sarah Kongpachith¹, WH Robinson¹, Sara Rasmussen², Robert Clancy³ and Jill P. Buyon³, ¹Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL) is an uncommon autoimmune disease classically manifest as permanent complete heart block and/or transient cutaneous lesions. By definition of NL, there…
Abstract Number: 1885 • 2015 ACR/ARHP Annual Meeting
Identification and Clinical Correlations of Rare Autoantibodies in Systemic Sclerosis and Poly/Dermatomyositis Patients
Angela Ceribelli^1,2, Natasa Isailovic³, Maria De Santis⁴, Elena Generali¹, Marco Massarotti⁵, Minoru Satoh⁶ and Carlo Selmi^7,8, ¹Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ²BIOMETRA, University of Milan, Milan, Italy, ³Internal Medicine; Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ⁴Internal Medicine, Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ⁵Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (Milan), Italy, ⁶Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ⁸BIOMETRA Department, University of Milan, Milan, Italy
Background/Purpose: Systemic Sclerosis (SSc), Polymyositis (PM) and Dermatomyositis (DM) are characterized by the presence of serum autoantibodies (autoAbs) which are central in the diagnosis, predicting…
Abstract Number: 2947 • 2015 ACR/ARHP Annual Meeting
Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Seiko Kondo-Ishikawa¹, Takao Fujii², Nozomi Ishigooka¹, Kosaku Murakami¹, Ran Nakashima¹, Yoshitaka Imura¹, Motomu Hashimoto², Naoichiro Yukawa¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Autoantibodies (auto Abs) in cerebrospinal fluid (CSF) and inflammatory mediators (IMs) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). Previous…
Abstract Number: 290 • 2015 ACR/ARHP Annual Meeting
Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients
Yves Allenbach¹, Jeremy Kaeren¹, Nicolas Champtiaux¹, Yoland Schoindre¹, Kuberaka Mariampillai¹, Aude Rigolet¹, Lucile Musset², Jean- Luc Charuel², Anthony Behin³, Bruno Eymard⁴, Pascal Laforet⁵, Tanya Stojkovic⁵, Olivier Boyer⁶, Baptiste Hervier⁷ and Olivier Benveniste¹, ¹Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ²Laboratoire d'immunochimie, Pitié- Salpêtrière, Paris, France, ³Institute of Myology, Pitie-Salpetriere Hospital, Paris, France, ⁴Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁵Department of Neurology, Myology Institute, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁶Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ⁷Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, Paris, France
Background/Purpose: Twenty percent of inflammatory myopathy are associated with a synchronous cancer occurring ±3 years around the diagnosis. Malignancy is a major cause of mortality…
Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting
B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
Shaun Jackson, Nicole Scharping, Holly Jacobs, Tanvi Arkatkar, Socheath Khim and David Rawlings, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…
Abstract Number: 1896 • 2015 ACR/ARHP Annual Meeting
Early Signs, Symptoms and Auto-Antibodies to Predict Diffuse Cutaneous or Limited Cutaneous Systemic Sclerosis at First Presentation
WMT van den Hombergh¹, HKA Knaapen-Hans¹, Patricia E. Carreira^2,3, FHJ van den Hoogen¹, Jaap Fransen¹ and MC Vonk¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³Rheumatology Unit, Hospital 12 de Octubre, Hospital 12 de Octubre, Madrid, Spain
ABSTRACT Background/Purpose: Diffuse cutaneous systemic sclerosis (dcSSc) is associated with a poorer prognosis compared to limited cutaneous SSc (lcSSc), due to earlier and more severe…
Abstract Number: 2995 • 2015 ACR/ARHP Annual Meeting
Genome Wide Analysis in Scleroderma Renal Crisis: Defining Genetic Risk in Patients with RNA Polymerase III Auto-Antibodies
Maria C Fonseca¹, Sandra Guerra¹, Edward Stern^1,2, Svetlana I. Nihtyanova¹, David Abraham³, Aine Burns², Mark Harber² and Christopher P. Denton⁴, ¹Rheumatology, UCL Division of Medicine, London, United Kingdom, ²Nephrology, Royal Free Hospital, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) is a severe complication of systemic sclerosis (SSc). Most SSc cases demonstrate a disease-specific antinuclear antibody including anti-RNA polymerase III…
Abstract Number: 398 • 2015 ACR/ARHP Annual Meeting
Clinical and Serological Profile of Children with Positive SSA-Ro/SSB-La Antibodies
Juan G. Ovalles-Bonilla¹, Juan C. Nieto¹, Francisco Javier López Longo¹, Julia Martínez-Barrio², Iustina Janta¹, Esperanza Naredo¹, Carlos M. Gonzalez¹, Michelle Hinojosa¹, Natalia Bello¹, Belen Serrano¹, Carmen Mata¹, Claudia Sáenz Tenorio¹, Diana C. Hernández¹, Lara Valor¹, Indalecio Monteagudo¹ and Luis Carreño¹, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Several studies have shown the relationship between anti-SSA-Ro/SSB-La antibodies and Systemic Lupus Erythematosus (SLE), Sjögren Syndrome (SS) and other autoimmune diseases in adult population.…
Abstract Number: 1119 • 2015 ACR/ARHP Annual Meeting
High Resolution Motif Mapping of in Situ Anti-Native-Vimentin Antibodies in Lupus Tubulointerstitial Nephritis
Andrew Kinloch¹, Yuta Asano², Balazs Banfai³, Gregor Dernick³, Carole Henry Dunand⁴, Nirit Mor-Vaknin⁵, Maureen Legendre⁵, David Markovitz⁵, Thomas Schindler⁶ and Marcus R. Clark⁷, ¹University of Chicago, Chicago, IL, ²Committee of immunology, University of Chicago, Chicago, IL, ³Translational Technologies and Bioinformatics, Roche, Basel, Switzerland, ⁴Rheumatology and Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵University of Michigan, Ann Arbor, MI, ⁶Roche Innovation Center Basel, Roche, Basel, Switzerland, ⁷Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL
Background/Purpose: Severe lupus tubulointerstitial nephritis (TIN) is prognostic of renal failure and characterized by an in situ autoantibody response. By characterizing monoclonal antibodies engineered from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.